Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Increasing dose of radioactive iodine in Graves' disease with historical control
TCTR20220322002Phase 3Completed
- Sponsor
- Prapokklao Hospital
- Start
- Jul 2022
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
A Phase 3 trial of iodine-131 in Graves' disease, sponsored by Prapokklao Hospital. Started Jul 2022; status: completed.
02
Drugs
iodine-131
03
Conditions
Graves' disease
Beyond the preview
Go deeper on TCTR20220322002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20220322002.